Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 3,100 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) CFO Andrew Guggenhime sold 3,100 shares of the stock in a transaction on Monday, April 18th. The shares were sold at an average price of $24.05, for a total value of $74,555.00. Following the completion of the transaction, the chief financial officer now directly owns 40,625 shares in the company, valued at approximately $977,031.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NASDAQ PCVX traded up $0.02 during trading on Wednesday, hitting $23.27. 242,783 shares of the company’s stock traded hands, compared to its average volume of 306,660. The business’s fifty day moving average price is $23.67. Vaxcyte, Inc. has a 12-month low of $15.51 and a 12-month high of $27.44. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -12.12 and a beta of 0.53.

Vaxcyte (NASDAQ:PCVX – Get Rating) last posted its quarterly earnings results on Monday, February 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.08). As a group, sell-side analysts expect that Vaxcyte, Inc. will post -2.62 EPS for the current year.

A number of research analysts recently commented on PCVX shares. Zacks Investment Research cut Vaxcyte from a “buy” rating to a “hold” rating in a research note on Wednesday, March 2nd. Needham & Company LLC restated a “buy” rating and set a $52.00 price target on shares of Vaxcyte in a research report on Thursday, February 24th.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Morgan Stanley grew its position in shares of Vaxcyte by 109.9% in the 2nd quarter. Morgan Stanley now owns 19,876 shares of the company’s stock worth $449,000 after buying an additional 10,405 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of Vaxcyte by 16.7% during the second quarter. Royal Bank of Canada now owns 2,922 shares of the company’s stock valued at $66,000 after acquiring an additional 418 shares in the last quarter. Invesco Ltd. bought a new position in shares of Vaxcyte during the second quarter valued at approximately $328,000. SG Americas Securities LLC bought a new position in shares of Vaxcyte during the third quarter valued at approximately $651,000. Finally, BlackRock Inc. raised its holdings in shares of Vaxcyte by 7.6% during the third quarter. BlackRock Inc. now owns 2,524,645 shares of the company’s stock valued at $64,051,000 after acquiring an additional 178,028 shares in the last quarter. Institutional investors and hedge funds own 89.74% of the company’s stock.

About Vaxcyte (Get Rating)

Vaxcyte, Inc, a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis.

Further Reading